News & Updates


 

pCODR invites stakeholders’ input on Pembrolizumab (Keytruda) for NSCLC

Please contact Lung Cancer Canada ([email protected]) if you are a patient or caregiver of a patient on Keytruda.  Your experience with this treatment is a crucial part of the decision process!

Renowned Public Health Physician's Battle Against Disease Was Personal

Tenacious Dr. Terry-Nan Tannenbaum, renowned public health physician, fought super-bugs, SARS, tuberculosis and HIV in others for decades until her fight became personal when she was diagnosed with terminal lung cancer.

Dr. Juergens' Interview with CTV News

Dr. Rosalyn Juergens' interview with Pauline Chan at CTV News on the promising results from the drug Opdivo (Nivolomab).

pCODR Releases Initial Recommendation of Opdivo

pCODR releases initial recommendation of Opdivo (nivolumab) for metastatic NSCLC (both squamous and non-squamous); on or after chemotherapy. No test required.  

This is a great news for NSCLC patients!  We hope to see more like this for other types of lung cancer.

Ontario’s Two-Tiered Cancer System is a Problem That Requires Immediate Treatment

Your experience with cancer care in Ontario depends greatly on the type of cancer you have, the kind of treatment you are prescribed, your age and family income – all of which can make or break the timeliness and quality of care you receive. Ontario’s two-tiered cancer drug system includes widely different drug reimbursement models and variable safety standards and support for patients who take their cancer medications at home versus in a hospital or cancer clinic.

Lung Cancer Screening Receives a Positive Recommendation

Some good news for Canada's deadliest cancer:
The Canadian Task Force on Preventive Health Care now recommends screening using low-dose CT scans in high-risk adults aged 55-74 years who are current or former smokers with a smoking history of at least 30 pack-years, defined as the average number of packs smoked daily multiplied by the number of years of smoking. This is big step in the fight against lung cancer! [Canadian Cancer Statistics, 2015]

Highlights of the Canadian Lung Cancer Conference 2016

In February 2016, 350 cancer specialists from across Canada gathered in Vancouver for the 16th annual Canadian Lung Cancer Conference chaired by Dr. Barb Melosky and Dr. Cheryl Ho. Participants included medical oncologists, radiation oncologists, surgeons, pathologists, oncology nurses as well as members of the pharmaceutical industry, who came together with a common interest in improving the care of patients with lung cancer in Canada.

Health Canada Approves Opdivo

Good news for lung cancer patients, OPDIVO™ (nivolumab), first-ever immunotherapy for advanced or metastatic NSCLC, gets Health Canada approval.

Call for Patient and Caregiver Engagement

LCC is looking for lung cancer patients and their caregivers, in Canada or the US, who have received either Cyramza (Ramucirumab), Keytruda (Pembrolizumab) or Tagrisso (Osimertinib) who are willing to share their experience (anonymously) with the drug.

End Stigma Now

At 26 and 5 months pregnant with her first child, non-smoker Elizabeth Dessureault never thought pregnancy would include a diagnosis of late stage lung cancer and chemotherapy. She was told that she had less than 1 year to live. At that point, the glow and hope of motherhood changed to include fear, a fight for her own life and the heavy stigma weight that lung cancer carries. 

Displaying results 111-120 (of 128)
 |<  <  4 - 5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13  >  >|